Comparison 18. PERPHENAZINE vs OLANZAPINE.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Leaving the study early: 1. Any reason	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 long term	2	657	Risk Ratio (M‐H, Random, 95% CI)	1.16 [1.05, 1.29]
2 Leaving the study early: 2. Due to adverse events	2	643	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.59, 1.21]
2.1 long term	2	643	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.59, 1.21]
3 Leaving the study early: 3. Due to relapse / worsening or no improvement	2	643	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.47, 3.29]
3.1 long term	2	643	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.47, 3.29]
4 Mental state: 1a. State ‐ BPRS end score (high = poor, skewed data)			Other data	No numeric data
4.1 long term			Other data	No numeric data
5 Mental state: 1b. State ‐ PANSS total endpoint score (high = poor, skewed data)			Other data	No numeric data
5.1 long term			Other data	No numeric data
6 Mental state: 1c. State ‐ PANSS: mean endpoint score from baseline (high = poor)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
6.1 total ‐ short term	1	60	Mean Difference (IV, Random, 95% CI)	4.21 [2.17, 6.25]
6.2 positive ‐ short term	1	60	Mean Difference (IV, Random, 95% CI)	8.23 [7.26, 9.20]
6.3 negative ‐ short term	1	60	Mean Difference (IV, Random, 95% CI)	1.58 [0.64, 2.52]
6.4 general psychopathology ‐ short term	1	60	Mean Difference (IV, Random, 95% CI)	‐0.39 [‐0.79, 0.01]
7 Mental state: 1d. State ‐ less than 25% PANSS reduction ('no effect')	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
7.1 short term	1	60	Risk Ratio (M‐H, Random, 95% CI)	2.0 [0.40, 10.11]
8 Adverse events: Movement disorders	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
8.1 akathisia ‐ long term	2	591	Risk Ratio (M‐H, Random, 95% CI)	1.33 [0.68, 2.60]
8.2 EPS ‐ long term	1	539	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.42, 1.49]
8.3 tardive dyskinesia ‐ long term	1	473	Risk Ratio (M‐H, Random, 95% CI)	1.28 [0.83, 1.95]
8.4 use of antiparkinsonian drugs ‐ long term	1	46	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.34, 26.76]
9 Other adverse events: 1. Anticholinergic	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
9.1 increased salivation ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	0.33 [0.01, 7.87]
10 Other adverse events: 2. Arousal	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
10.1 agitation ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.33, 27.23]
10.2 anxiety ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	1.25 [0.37, 4.21]
10.3 insomnia ‐ long term	2	657	Risk Ratio (M‐H, Random, 95% CI)	2.34 [0.62, 8.89]
10.4 sleepiness/ sedation ‐ long term	1	597	Risk Ratio (M‐H, Random, 95% CI)	0.92 [0.71, 1.18]
11 Other adverse events: 3. Cardiovascular	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
11.1 bradycardia ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.13, 70.83]
11.2 faintness, dizziness, weakness ‐ long term	1	597	Risk Ratio (M‐H, Random, 95% CI)	1.20 [0.75, 1.95]
11.3 hypotension ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	0.33 [0.01, 7.87]
12 Other adverse events: 4. Central nervous system	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
12.1 headache ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	0.71 [0.25, 2.00]
12.2 hypertonia ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.13, 70.83]
13 Other adverse events: 5. Gastrointestinal	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
13.1 gastroenteritis ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.13, 70.83]
13.2 weight gain ‐ long term	1	550	Risk Ratio (M‐H, Random, 95% CI)	0.40 [0.27, 0.58]
14 Other adverse events: 6. Skin	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
14.1 cellulitis ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	0.33 [0.01, 7.87]
14.2 eczema ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.13, 70.83]
14.3 fungal dermatitis ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	0.33 [0.01, 7.87]
14.4 rash ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	1.0 [0.07, 15.26]
15 Other adverse events: 7. Genitourinary	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
15.1 diminished sexual desire ‐ long term	1	597	Risk Ratio (M‐H, Random, 95% CI)	0.91 [0.69, 1.19]
15.2 galactorrhea/ gynaecomastia ‐ long term	1	597	Risk Ratio (M‐H, Random, 95% CI)	0.74 [0.22, 2.49]
16 Other adverse events: 8. Others	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
16.1 allergic reaction ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	0.33 [0.01, 7.87]
16.2 back pain ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.13, 70.83]
16.3 incontinence nocturia ‐ long term	1	597	Risk Ratio (M‐H, Random, 95% CI)	0.43 [0.17, 1.07]
16.4 suicide attempt ‐ long term	1	597	Risk Ratio (M‐H, Random, 95% CI)	0.64 [0.06, 7.06]
16.5 urinary hesitancy, dry mouth, constipation ‐ long term	1	597	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.69, 1.25]
17 Other adverse events: 9. any serious adverse event	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
17.1 long term	1	597	Risk Ratio (M‐H, Random, 95% CI)	1.17 [0.72, 1.88]
18 Other adverse events: 10. lab data	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
18.1 anemia ‐ long term	1	60	Risk Ratio (M‐H, Random, 95% CI)	1.0 [0.07, 15.26]
19 Other adverse events: 11a. lab data	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
19.1 mean weight change (lb) ‐ long term	1	597	Mean Difference (IV, Random, 95% CI)	‐11.4 [‐14.19, ‐8.61]
19.2 change in blood glucose ‐ long term	1	597	Mean Difference (IV, Random, 95% CI)	‐9.8 [‐16.54, ‐3.06]
19.3 change in glycosylated haemoglobin ‐ long term	1	597	Mean Difference (IV, Random, 95% CI)	‐0.31 [‐0.52, ‐0.10]
19.4 change in cholesterol ‐ long term	1	597	Mean Difference (IV, Random, 95% CI)	‐9.2 [‐15.30, ‐3.10]
19.5 change in triglycerides ‐ long term	1	597	Mean Difference (IV, Random, 95% CI)	‐34.60 [‐62.51, ‐6.69]
19.6 change in prolactin ‐ long term	1	597	Mean Difference (IV, Random, 95% CI)	6.5 [2.42, 10.58]
20 Other adverse events: 11b. lab data (skewed)			Other data	No numeric data
20.1 weight change			Other data	No numeric data